Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06691217 | Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis | PHASE2 | RECRUITING | 120 | — | — | Apr 1, 2026 | Apr 1, 2030 | Apr 14, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Placebo: Control | PLACEBO_COMPARATOR | Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal. |
| Treatment: Canakinumab | EXPERIMENTAL | Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal. |
| Name | Type | Description |
|---|---|---|
| CANAKINUMAB (ILARIS®) | DRUG | Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal. |
| Saline (NaCl 0,9 %) (placebo) | DRUG | Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal. |
Inclusion Criteria: * 18 years or older * Prior heart attack or coronary stent procedure \>180 days before baseline imaging * Presence of either TET2 CHIP or no CHIP variants on prior sequencing Exclusion Criteria: * placement of a drug-eluting stent in a proximal coronary arterial segment \<180 ...